Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial

Table 1

Demographic characteristics of the study population.

Characteristic	Total SES n = 5,781	nAMD n = 3,631	DME n = 1,226	RVO n = 744
Gender
Male	2,530 (43.8%)	1,401 (38.6%)	705 (57.5%)	353 (47.5%)
Female	3,235 (56.0%)	2,222 (61.2%)	515 (42.0%)	389 (52.3%)
Missing	16 (0.3%)	8 (0.2%)	6 (0.5%)	2 (0.3%)
Age (years)
Mean (SD)	74.6 (10.3)	77.9 (8.1)	67.6 (10.8)	71.0 (10.9)
BMI (kg/m^2)
Mean (SD)	27.2 (4.5)	26.6 (4.0)	29.3 (5.2)	27.1 (4.3)
Total number of injections per patient (observational period)
Mean (SD)	5.7 (3.8)	5.7 (3.7)	5.5 (3.6)	6.0 (4.1)

Due to low patient numbers for the mCNV population, a breakdown by demographic characteristics is not presented. BMI, body mass index; DME, diabetic macular edema; mCNV, myopic choroidal neovascularization; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion; SD, standard deviation; SES, safety evaluation set.